BA
SUPN icon

BlackRock Advisors’s Supernus Pharmaceuticals SUPN Stock Holding History

BlackRock Advisors’s Portfolio SUPN Stock Details SUPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		$640K Sell
25,334
-9,617
-28% -$215K ﹤0.01% 2071
2016
Q3 		$864K Buy
34,951
+14,223
+69% +$322K ﹤0.01% 1902
2016
Q2 		$422K Buy
20,728
+4,906
+31% +$87K ﹤0.01% 2208
2016
Q1 		$241K Buy
15,822
+940
+6% +$12.3K ﹤0.01% 2466
2015
Q4 		$200K Sell
14,882
-7,112
-32% -$110K ﹤0.01% 2570
2015
Q3 		$309K Buy
21,994
+330
+2% +$6.14K ﹤0.01% 2489
2015
Q2 		$368K Buy
21,664
+5,652
+35% +$80.4K ﹤0.01% 2402
2015
Q1 		$194K Buy
16,012
+2,273
+17% +$21.5K ﹤0.01% 2691
2014
Q4 		$114K Buy
13,739
+1,729
+14% +$14.5K ﹤0.01% 2969
2014
Q3 		$104K Sell
12,010
-352
-3% -$3.18K ﹤0.01% 2979
2014
Q2 		$135K Buy
12,362
+1,719
+16% +$15.3K ﹤0.01% 2885
2014
Q1 		$95K Buy
10,643
+2,734
+35% +$25.2K ﹤0.01% 3053
2013
Q4 		$60K Buy
7,909
+938
+13% +$6.56K ﹤0.01% 3200
2013
Q3 		$51K Buy
6,971
+228
+3% +$1.53K ﹤0.01% 3177
2013
Q2 		$43K Buy
+6,743
New +$39.7K ﹤0.01% 3196

Other funds holding SUPN

BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
RIM
Ranger Investment Management Dallas, Texas $1.38B AUM 24.55% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
GT
Glenmede Trust Philadelphia, Pennsylvania $20.4B AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

BlackRock Advisors's SUPN Position: Q4 2016 in Review

BlackRock Advisors reduced its Supernus Pharmaceuticals (SUPN) stake by 28% in Q4 2016, selling an estimated $215K and leaving 25,334 shares worth $640K. The position accounts for ﹤0.01% of the portfolio, ranked #2071.

BlackRock Advisors first reported a position in SUPN in Q2 2013 and has held it in 15 quarters since. The position peaked at $864K in Q3 2016. 233 funds tracked by Wall St. Rank hold SUPN as of Q4 2016.

  • BlackRock Advisors held 25,334 shares of Supernus Pharmaceuticals worth $640K as of Q4 2016.
  • BlackRock Advisors sold 9,617 Supernus Pharmaceuticals shares in Q4 2016, an estimated $215K.
  • Supernus Pharmaceuticals made up ﹤0.01% of BlackRock Advisors's portfolio in Q4 2016, its #2071 holding.
  • BlackRock Advisors first reported a position in Supernus Pharmaceuticals in Q2 2013 and has held it in 15 quarters since.
  • BlackRock Advisors's Supernus Pharmaceuticals position peaked at $864K in Q3 2016.
  • 233 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q4 2016.

Based on BlackRock Advisors's 13F filing for Q4 2016, filed 10 Feb 2017.